APA (7th ed.) Citation

Tarkiainen, M., Tynjälä, P., Vähäsalo, P., Aalto, K., Kröger, L., Rebane, K., . . . Martikainen, J. (2022). Economic evaluation of infliximab, synthetic triple therapy and methotrexate in the treatment of newly diagnosed juvenile idiopathic arthritis. Pediatric Rheumatology, 20(1), 1. https://doi.org/10.1186/s12969-022-00748-w

Chicago Style (17th ed.) Citation

Tarkiainen, Maarit, Pirjo Tynjälä, Paula Vähäsalo, Kristiina Aalto, Liisa Kröger, Katariina Rebane, Pekka Lahdenne, and Janne Martikainen. "Economic Evaluation of Infliximab, Synthetic Triple Therapy and Methotrexate in the Treatment of Newly Diagnosed Juvenile Idiopathic Arthritis." Pediatric Rheumatology 20, no. 1 (2022): 1. https://doi.org/10.1186/s12969-022-00748-w.

MLA (9th ed.) Citation

Tarkiainen, Maarit, et al. "Economic Evaluation of Infliximab, Synthetic Triple Therapy and Methotrexate in the Treatment of Newly Diagnosed Juvenile Idiopathic Arthritis." Pediatric Rheumatology, vol. 20, no. 1, 2022, p. 1, https://doi.org/10.1186/s12969-022-00748-w.